Humacyte, Inc. - Common Stock (HUMA)

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Humacyte Inc (HUMA) Q2 2025 earnings show a revenue miss of 70%, with shares dropping ~9.9% pre-market. Hospital approvals grow, but commercial adoption lags.

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Trump's tariff delay caused the small-cap stocks in iShares Russell 2000 ETF to rise significantly. Semiconductor components were also top performers.

Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.

Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.

Humacyte shares are trading lower by 29% during Wednesday's session. The company priced a $50 million public offering.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.